Hepatic Complication clinical trials at UC Davis
1 research study open to eligible people
Trametinib (targeted chemotherapy) in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
“Study looking at experimental, targeted chemotherapy (Trametinib) to treat advanced cancers”
open to eligible people ages 18 years and up
This phase I trial studies the side effects and best dose of trametinib in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) with or without liver (hepatic) dysfunction. Trametinib may stop the growth of tumor cells by blocking proteins needed for cell growth. When these proteins are blocked, the growth of cancer cells may be stopped and the cancer cells will then die. Hepatic dysfunction is frequently found in patients with advanced cancer and usually prevents patients from receiving standard treatments or from participating in clinical trials. Patients may also need dose adjustments or absorb drugs differently. Trametinib may be a better treatment for patients with advanced cancers and hepatic dysfunction.
Sacramento, California and other locations